The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
5-Fluorouracil: Forty-Plus and Still Ticking. A Review of its Preclinical and Clinical Development
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
Morris, M., Eifel, P. J., Lu, J., Grigsby, P. W., Levenback, C., Stevens, R. E., Rotman, M., Gershenson, D. M., & Mutch, D. G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904153401501 · Cited by 2,299
Herskovic, A., Martz, K., Al-Sarraf, M., Leichman, L., Brindle, J., Vaitkevicius, V., Cooper, J., Byhardt, R., Davis, L., & Emami, B. (1992) · New England Journal of Medicine · doi:10.1056/nejm199206113262403 · Cited by 2,108
Cooper, J. S., Guo, M. D., Herskovic, A., Macdonald, J. S., Martenson, Jr., Al-Sarraf, M., Byhardt, R., Russell, A. H., Beitler, J. J., Spencer, S., et al. (1999) · JAMA · doi:10.1001/jama.281.17.1623 · Cited by 1,957
Fluorinated pyrimidines, a new class of tumour-inhibitory compounds
HEIDELBERGER, C., CHAUDHURI, N. K., DANNEBERG, P., MOOREN, D., GRIESBACH, L., DUSCHINSKY, R., SCHNITZER, R. J., PLEVEN, E., & SCHEINER, J. (1957) · Nature · doi:10.1038/179663a0 · Cited by 1,603
Bartelink, H., Roelofsen, F., Eschwege, F., Rougier, P., Bosset, J. F., Gonzalez, D. G., Peiffert, D., van Glabbeke, M., & Pierart, M. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.2040 · Cited by 1,319
(1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.896 · Cited by 1,189
O'Connell, M. J., Martenson, J. A., Wieand, H. S., Krook, J. E., Macdonald, J. S., Haller, D. G., Mayer, R. J., Gunderson, L. L., & Rich, T. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408253310803 · Cited by 1,136
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.301 · Cited by 981
Cited by
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
5-Fluorouracil: Mechanisms of Resistance and Reversal Strategies
Zhang, N., Yin, Y., Xu, S.-J., & Chen, W.-S. (2008) · Molecules · doi:10.3390/molecules13081551 · Cited by 771
ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Choi, Y., & Yu, A.-M. (2014) · Current Pharmaceutical Design · doi:10.2174/138161282005140214165212 · Cited by 629
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil
van Kuilenburg, A. B. P. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.12.004 · Cited by 488
Nepali, K., Sharma, S., Sharma, M., Bedi, P. M. S., & Dhar, K. L. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.03.018 · Cited by 435
5-fluorouracil and cardiotoxicity: a review
Sara, J. D., Kaur, J., Khodadadi, R., Rehman, M., Lobo, R., Chakrabarti, S., Herrmann, J., Lerman, A., & Grothey, A. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918780140 · Cited by 433
Shelton, J., Lu, X., Hollenbaugh, J. A., Cho, J. H., Amblard, F., & Schinazi, R. F. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00209 · Cited by 409
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): A review
Malet-Martino, M., & Martino, R. (2002) · The Oncologist · doi:10.1634/theoncologist.7-4-288 · Cited by 382
Wei, L., Wang, X., Lv, L., Liu, J., Xing, H., Song, Y., Xie, M., Lei, T., Zhang, N., & Yang, M. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1086-z · Cited by 339
Inhibition of Autophagy by 3-MA Enhances the Effect of 5-FU-Induced Apoptosis in Colon Cancer Cells
Li, J., Hou, N., Faried, A., Tsutsumi, S., Takeuchi, T., & Kuwano, H. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0260-0 · Cited by 291
“subsequently, cause the DNA strand to break and eventually lead to apoptosis in the cancer cell.(10) The ability of tumor cells to undergo apoptosis by drug treatment is important regarding sensitivity to chemotherapy,(4,11) and enhancing the apoptosis of tumor cells in response to 5-FU might improve the effects of ch…”
BackgroundRosmarin, D., Palles, C., Church, D., Domingo, E., Jones, A., Johnstone, E., Wang, H., Love, S., Julier, P., Scudder, C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.1857 · Cited by 256
5-Fluorouracil treatment induces characteristic T>G mutations in human cancer
(2019) · doi:10.1038/s41467-019-12594-8 · Cited by 201
Nanocellulose/Gelatin Composite Cryogels for Controlled Drug Release
Li, J., Wang, Y., Zhang, L., Xu, Z., Dai, H., & Wu, W. (2019) · ACS Sustainable Chemistry & Engineering · doi:10.1021/acssuschemeng.9b00161 · Cited by 136
Bravo Ruiz, G., Ross, Z. K., Gow, N. A. R., & Lorenz, A. (2020) · mSphere · doi:10.1128/msphere.00151-20 · Cited by 101
Nano drug delivery strategy of 5-fluorouracil for the treatment of colorectal cancer
Chandran, S. P., Natarajan, S. B., Chandraseharan, S., & Mohd Shahimi, M. S. B. (2017) · Journal of Cancer Research and Practice · doi:10.1016/j.jcrpr.2017.02.002 · Cited by 97
Metadata
- Authors
- Grem, J. L.
- Venue
- Investigational New Drugs
- Published
- 2000-11
- Volume
- 18
- Issue
- 4
- Pages
- 299-313
- ISSN
- 0167-6997 (ISSN-L)
- 1573-0646
- OpenAlex
- W102725257
- Cited by
- 417
- References
- 80
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.